Grenitab MD Tablet contains Granisetron 1 mg, a selective 5-HT3 receptor antagonist used primarily for the prevention and treatment of nausea and vomiting induced by chemotherapy, radiotherapy, and postoperative conditions. Granisetron exerts its antiemetic effect by blocking serotonin receptors located on vagal nerve terminals and in the chemoreceptor trigger zone, thereby inhibiting the initiation of the vomiting reflex. This medication is indicated for patients undergoing highly emetogenic cancer treatments to improve quality of life and adherence to therapeutic regimens. Grenitab MD is administered orally, providing convenient dosing with rapid onset of action and a favorable safety profile. Common adverse effects may include headache, constipation, and transient elevation of liver enzymes, though it is generally well tolerated. Caution is advised in patients with hepatic impairment, and dosage adjustments may be necessary. It should be used under medical supervision, with attention to potential drug interactions, especially with other serotonergic agents. Grenitab MD Tablet offers an effective option for managing chemotherapy-induced nausea and vomiting, contributing significantly to supportive care in oncology settings. Proper adherence to prescribed dosing schedules is essential to maximize therapeutic benefits and minimize adverse effects.